Eisai Launches Sedative-Hypnotic Agent LUSEDRA™ Injection CIV in the United States
Eisai Inc. (Headquarters: New Jersey, the United States, President and CEO: Hajime Shimizu), a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito), today announced the U.S. launch of LUSEDRA™ (generic name: fospropofol disodium) Injection, an intravenous sedative-hypnotic agent, that is to be used by healthcare professionals trained in the administration of general anesthesia.
LUSEDRA is a proprietary water-soluble prodrug of propofol that, after intravenous injection, is converted by alkaline phosphatase enzymes in the body into propofol prior to exerting sedative effects.
The U.S. Food and Drug Administration (FDA) approved LUSEDRA in December 2008 for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures. The agent is designated as a Schedule IV controlled substance.
With the launch of LUSEDRA, Eisai is able to provide a new option for sedation for patients undergoing diagnostic or therapeutic procedures and remains committed to making further contributions to addressing the diversified needs and increasing the benefits of patients and healthcare professionals.
[ Please refer to the following notes for the U.S. product outline ]
Public Relations Department
Eisai Co., Ltd.
+81 - (0)3 - 3817 - 5120
< Notes to editors >
U.S. Product Outline of LUSEDRA™
LUSEDRA™ Injection CIV
Injection solution for intravenous administration
Indication and Usage:
LUSEDRA is indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.
Dosage and Administration:
Warnings and Precautions:
LUSEDRA should be administered only by persons trained in the administration of general anaesthesia and not involved in the conduct of the diagnostic or therapeutic procedure. Sedated patients should be continuously monitored, and facilities for maintenance of a patent airway, providing artificial ventilation, administering supplemental oxygen, and instituting cardiovascular resuscitation must be immediately available. Patients should be continuously monitored during sedation and through the recovery process for early signs of hypotension, apnea, airway obstruction, and/or oxygen desaturation.
Serious adverse reactions such as apnea, hypoxemia, loss of purposeful responsiveness, or hypotension were reported in patients treated with LUSEDRA. The most common adverse reactions reported in greater than 20% are paresthesia and pruritus.